Page last updated: 2024-08-24

lurtotecan and Local Neoplasm Recurrence

lurtotecan has been researched along with Local Neoplasm Recurrence in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baron, B; Bloch, J; Borner, M; Chollet, P; Degardin, M; Dittrich, C; Duffaud, F; Fumoleau, P; Lacombe, D; Rolland, F; Vermorken, JB1
Barrett, E; Calvert, AH; Cameron, T; Coleman, R; Dark, GG; Eisenhauer, EA; Ellard, S; Grimshaw, R; Hamilton, M; Jayson, G; Kaye, S; Le, T; McIntosh, L; Poole, C; Swenerton, K; Trudeau, M; Vasey, P; Walsh, W1

Trials

2 trial(s) available for lurtotecan and Local Neoplasm Recurrence

ArticleYear
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis

2004
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Canada; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms

2005